Clinical Study
Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
Table 1
Patient characteristics.
| | Total enrolled patients, (%) | 104 | | Cycle 1 | 104 (100.0) | | Cycle 4 | 75 (72.1) | | Cycles of bortezomib treatment, mean ± SD | 4.6 ± 2.2 | | Sex, , M/F (%) | 56/48 (53.9/46.1) | | Age at treatment, , <65/≥65 (%) | 67/37 (64.4/35.6) | | ECOG performance status, (%) | | | 0 | 23 (22.1) | | 1 | 56 (53.9) | | 2 | 23 (22.1) | | 3 | 2 (1.9) | | 4 | 0 | | Quantity of M-protein (g/L) in SPEP, median (range) | 1.3 (0.0–6.7) | | Hb ≤ 10.0 g/dL, /median (%/range) | 41/10.7 (39.4/6.9–15.3) | | Platelet, median, (range) | 203.0 (30.0–760.0) | | Creatinine, median (range) | 0.98 (0.5–5.6) | | Calcium (g/dL), median (range) | 8.7 (6.5–11.1) | | LDH > 472 IU/L, /median (%/range) | 20/350.0 (19.2/15.0–1452.0) | | Albumin (g/L), median (range) | 3.7 (2.4–6.4) | Stage, (%)
Durie-Salmon Staging System | | | I | 13 (12.5) | | II | 21 (20.2) | | III | 70 (67.3) | Stage, (%)
International Staging System | | | I | 15 (14.4) | | II | 44 (42.3) | | III | 45 (43.3) | | Previous treatment, (%) | | | VAD | 37 (35.6) | | MP | 30 (28.9) | | Dexamethasone | 29 (27.9) | | ASCT | 21 (20.2) | | Thalidomide | 19 (18.3) | | Others | 21 (20.2) |
|
|
VAD: vincristine + Adriamycin + dexamethasone; MP: melphalan + prednisolone; ASCT: autologous stem cell transplantation.
|
